Purpose: While immune checkpoint inhibitors are disrupting the management of patients with cancer, anecdotal occurrences of rapid progression (i.e., hyperprogressive disease or HPD) under these agents have been described, suggesting potentially deleterious effects of these drugs. The prevalence, the natural history, and the predictive factors of HPD in patients with cancer treated by anti-PD-1/...

Background and Objective: Anti-inflammatory property of nobiletin (NOB) is proven and neuroinflammation is involved in triggering and progression of neurodegenerative disorder such as Parkinson's disease (PD). PD is a neurodegenerative disorder characterized by motor and non-motor features including psychiatric symptoms such as depression and anxiety. The purpose of this study to investigate wh...

Osteosarcoma (OS) is a primary bone malignancy, commonly culminating into aggressive pulmonary metastasis. Despite chemotherapy advances, the 5-year survival of pulmonary metastatic OS remains 25-30%. Immunotherapy is one of the promising novel approaches to target minimal residual and relapsed disease. Previously, we have demonstrated that Liposomal muramyl tripeptipe phosphatidyl ethanolamine...

BACKGROUND/OBJECTIVE Anti-inflammatory drugs may prevent Parkinson disease (PD) by inhibiting a putative underlying neuroinflammatory process. We tested the hypothesis that anti-inflammatory drugs reduce PD incidence and that there are differential effects by type of anti-inflammatory, duration of use, or intensity of use. METHODS MEDLINE and EMBASE were searched for studies that reported ris...

Background: Over the past decade, treatment landscape for advanced hepatocellular carcinoma (HCC) has expanded considerably. Therefore, this network meta-analysis aimed to compare efficacy of combination versus sorafenib. Materials and Methods: A systematic literature review was conducted select eligible studies. performed overall survival (OS) objective respon...

Immunotherapy based on blockade of the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis has shown promising clinical activity for renal cell carcinoma (RCC) patients; however, the most effective use of these agents in combination with conventional targeted therapy remains to be resolved. Here we evaluated the therapeutic efficacy of the combination of the mTOR inhibitor everolim...

BACKGROUND Programmed cell death protein 1 (PD-1) plays an important role in immune response regulation as a co-inhibitory signal during T cell activation. However, there is little known about the serum autoantibody profile of PD-1 in systemic lupus erythematosus (SLE), a disease characterized by the breakdown of immune tolerance to self-antigens and an excessive production of autoantibodies. T...

Although PD-1 blockade therapy demonstrates promising therapeutic effects in a portion of metastatic melanoma patients, clinical outcomes remain variable, with some patients achieving durable responses, others experiencing early disease worsening followed by later tumor reduction, while some show no benefit. Thus, it is critical to identify patients with melanoma who are most likely to benefit ...